WI-ROCKWELL-AUTOMATION
13.3.2024 12:01:34 CET | Business Wire | Press release
Rockwell Automation Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has been selected by Church & Dwight Co., Inc. (NYSE: CHD) to strengthen the consumer goods company’s cybersecurity program. Church & Dwight chose Rockwell specifically to help build resiliency and minimize risks in its operational technology (OT) manufacturing security practices.
The number of cyberattacks against manufacturing and critical infrastructure continues to rise. A recent report found critical manufacturing was one of the most frequently attacked verticals in the OT/industrial control system (ICS) sector. With several global consumer brands under its umbrella, Church & Dwight recognized the critical impact and importance of a strong OT security posture and enlisted Rockwell. The goal was to gain a deeper understanding of its manufacturing risk profile by identifying critical assets, vulnerabilities and security gaps. After examining and prioritizing risk, Rockwell collaborated with Church & Dwight to develop a remediation roadmap, new security policies, and other measures to minimize risks.
“We selected Rockwell Automation because we were looking for a new partner to help us uplevel our OT and manufacturing security posture. We knew we needed the best of the best who understood our vision,” said David Ortiz, chief information security officer (CISO) at Church & Dwight. “Throughout our work with Rockwell Automation on our OT cybersecurity program, we’ve gained a thorough understanding of our cybersecurity landscape and the tools needed.”
“At Rockwell Automation, we firmly believe in helping organizations recognize the importance of OT cybersecurity,” said Mark Cristiano, global commercial director at Rockwell. "Over the course of our partnership with Church & Dwight, we have implemented new security controls and processes and have already seen a dramatic shift in the company's OT practices. We are proud to leverage our best-in-class partnerships to help Church & Dwight achieve its cybersecurity goals.”
As a longtime Rockwell Industrial Solutions customer, Church & Dwight expanded its partnership in 2020 to advance their Manufacturing Cybersecurity Program initiative. Since then, Church & Dwight has achieved its cybersecurity objectives in mitigating risks and understanding its OT landscape. Once threat detection capabilities were in place, Church & Dwight implemented continuous monitoring through managed OT services from Rockwell. These managed services integrate and support Church & Dwight’s current IT Security Operations Center, bridging the gap between IT and OT networks, and mitigating cyber risks across the enterprise.
To read more about the Church & Dwight and Rockwell Automation partnership, visit: https://www.rockwellautomation.com/en-us/company/news/case-studies/church-dwight-ot-cybersecurity.html
About Church & Dwight
Church & Dwight Co., Inc., founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household, and specialty products under recognized brand names such as ARM & HAMMER®, TROJAN™, OXICLEAN™, SPINBRUSH™, FIRST RESPONSE™, NAIR™, ORAJEL™, XTRA™, L’IL CRITTERS™ and VITAFUSION™, BATISTE™, WATERPIK®, ZICAM®, THERABREATH™, and HERO MIGHTY PATCH®. These 14 key brands represent approximately 85% of the Company’s product sales. For more information, visit the Company’s website.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK) is a global leader in industrial automation and secure digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit www.rockwellautomation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313204374/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom